Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q2 FY2019 Earnings Presentation
13 slides from Dr. Reddy's Laboratories's earnings presentation, Oct 26, 2018
Slide 1: Press Presentation – Q2 FY19
Press Presentation – Q2 FY19 1 | October 26, 2018 | Q2 FY19 Press Meet
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Q2 Financial highlights
% to Sales Q2 Financial highlights Revenue (` Cr) YoY QoQ Gross profit (%) 7% 2% 3,798 55.7% 55.0% 3,721 53.3% 3,546 Q2 FY18 Q1 FY19 Q2 FY19 Q2 FY18 Q1 FY19 Q2 FY19 YoY QoQ YoY QoQ R&D (` Cr) -1% -1% EBITDA (` Cr) 26% 7% 418 416 865 412 807 689 11.8 11.2 10.8 19.4 21.7 22.8 Q2 FY18 Q1 FY19 Q2 FY19 Q
Slide 4: Q2 FY19: Global Generics revenues of Rs. 3,054 Cr
Q2 FY19: Global Generics revenues of Rs. 3,054 Cr (YoY Growth: 7%, QoQ: Flat) North America: ` 1,427 Cr Emerging Markets: ` 749 Cr YoY Flat YoY Growth: 36% QoQ Decline : 10% Europe: ` 191 Cr QoQ Growth: 13% YoY Decline: 21% QoQ Decline: 5% India: ` 686 Cr YoY Growth: 8% QoQ Growth: 13% 4 | October 2
Slide 5: North America Generics
North America Generics YoY QoQ Revenues (` Cr) Flat -10% Market Share Generics filings update Product Aug-18 May-18 292 cumulative filings 1,590 Liposomal Doxorubicin^ 51% 50% (288 ANDAs, 4 NDAs) Decitabine^ 50% 46% 1,432 1,427 Ezeti+Simva 31% 30% Metoprolol ER 26% 29% 113 pending approvals Azacitid
Slide 6: India
India Commentary Revenues (` Cr) YoY QoQ 8% 13 % YoY & QoQ growth driven by new product launches and improvement in the base business performance. 686 6 new products launched during the quarter. 637 607 IMS Growth rates (Aug’18): August 2018 MQT MAT Q2 FY18 Q1 FY19 Q2 FY19 IPM 13.7% 10.8% Dr.
Slide 7: Emerging Markets
Emerging Markets YoY QoQ Revenues (` Cr) 36% 13% Commentary 749 Russia 664 In local currency terms, YoY sales grew by 21%. Growth majorly 226 551 due to new launches & improved volume uptake during the current 167 137 quarter. 118 144 92 CISR 379 379 Growth driven by higher sales in Ukraine, Kaz
Slide 8: Pharmaceutical services & active ingredients
Pharmaceutical services & active ingredients Revenues (` Cr) YoY QoQ Commentary 7% 11 % YoY & QoQ growth is on account of volume traction in some 603 of our key molecules 565 Globally, 6 DMFs were filed in this quarter, of which 1 was in 541 the US Cumulative DMF Filings Region Filings US 204 Eu
Slide 9: Capex, R&D & free cash flows
Capex, R&D & free cash flows R&D expenses (` Cr) Capex (` Cr) 828 1,202 1,228 1,745 1,783 1,955 1,826 371 934 925 412 136 416 235 FY15 FY16 FY17 FY18 H1 FY19 FY15 FY16 FY17 FY18 H1 FY19 Q1 Q2 Q1 Q2 Free cash flow (` Cr) Net Debt / Equity FY15 FY16 FY17 FY18 H1 FY19 2,827 201 0.25 0.29 0.26 0.24 1,46
Slide 10: Key Priorities
Key Priorities Actively work with the regulatory agencies for accelerating the new product approvals Continue on our journey of strengthening the quality systems and processes Strengthening our portfolio across markets, and grow better than the market growth rate Cost optimization and producti
Slide 11: Q&A SESSION
Q&A SESSION 11 | October 26, 2018 | Q2 FY19 Press Meet
Slide 12: THANK YOU
THANK YOU
Slide 13: Contact
CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com CALVIN PRINTER calvinprinter@drreddys.com (PH: +91-40-49002135) (Ph: +91-40- 49002121) ………………………………………………………………………………………………………………………………………………………..…………………………..… About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
Dr. Reddy's Laboratories — Q2 FY2019 Earnings Presentation on 6ix